US govt sends drugmakers initial offers in price talks

US govt sends drugmakers initial offers in price talks

US President Joe Biden's administration has sent initial offers to makers of drugs selected for price negotiations
US President Joe Biden's administration has sent initial offers to makers of drugs selected for price negotiations. Photo: Oliver Contreras / GETTY IMAGES NORTH AMERICA/Getty Images via AFP/File
Source: AFP

The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

The move comes as President Joe Biden pushes to rein in health care costs ahead of November's election.

The negotiation program came on the back of Biden's landmark Inflation Reduction Act, a major package of energy transition policy and social reforms.

This allowed Medicare, the federal health insurance for seniors, to start negotiating drug costs -- a first in its nearly 60-year existence.

"This is the first time ever that Medicare is not accepting the drug prices the pharmaceutical companies set," the White House said in a statement on Thursday.

It did not reveal how much it offered for each drug.

Read also

IMF says central banks should not rush into rate cuts

PAY ATTENTION: Watch the hottest celebrity stories on our YouTube channel 'Briefly TV'. Subscribe now!

A Johnson & Johnson spokesperson told AFP the company has received an initial price from the government but said it was "respecting the confidential nature of the process."

Last October, major drugmakers behind 10 selected medicines for serious illnesses grudgingly agreed to negotiate on cutting prices.

But pharmaceutical companies have pushed back against the initiative, earlier saying that they came on board as they had no choice.

While the US government is initially limited to picking 10 drugs for price talks, it can expand the program in subsequent years.

The drugs include Farxiga by AstraZeneca used against diabetes, Entresto by Novartis to treat heart failure, as well as anticoagulant Eliquis -- used by millions of Medicare beneficiaries.

According to the White House, nine million seniors on Medicare were prescribed the 10 drugs in 2022, spending some $3.4 billion out-of-pocket that year.

Read also

Publicis settles opioid case with US states for $350 mn

The statement also took aim at Big Pharma, which the White House said "charged Americans two to three times more" than in other countries, even when accounting for rebates and discounts.

Biden, who is campaigning for reelection with a large focus on easing voters' financial burdens, said in a separate statement: "My Administration won't stop fighting to lower health care costs for seniors and families."

New negotiated prices for the 10 prescription drugs are set to be announced later this year.

Medicare is expected to negotiate prices for up to 60 drugs over the next four years, and up to an additional 20 drugs each year after that.

Several companies have taken legal action challenging the provisions.

PAY ATTENTION: Сheck out news that is picked exactly for YOU - click on “Recommended for you” and enjoy!

Source: AFP

Authors:
AFP avatar

AFP AFP text, photo, graphic, audio or video material shall not be published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP news material may not be stored in whole or in part in a computer or otherwise except for personal and non-commercial use. AFP will not be held liable for any delays, inaccuracies, errors or omissions in any AFP news material or in transmission or delivery of all or any part thereof or for any damages whatsoever. As a newswire service, AFP does not obtain releases from subjects, individuals, groups or entities contained in its photographs, videos, graphics or quoted in its texts. Further, no clearance is obtained from the owners of any trademarks or copyrighted materials whose marks and materials are included in AFP material. Therefore you will be solely responsible for obtaining any and all necessary releases from whatever individuals and/or entities necessary for any uses of AFP material.